JAMES GREENFIELD: Open Payments
NPI 1396700845 · FRACKVILLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,856 in 105 payments from 18 companies in 2025. Trend: 2023 $5,301 · 2024 $2,553 · 2025 $1,856
Food & beverage: $1,856
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $320 |
| AstraZeneca Pharmaceuticals LP | 11 | $269 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $209 |
| Braeburn Inc. | 14 | $173 |
| Lilly USA, LLC | 9 | $147 |
| Otsuka America Pharmaceutical, Inc. | 5 | $96 |
| Novo Nordisk Inc | 5 | $93 |
| GlaxoSmithKline, LLC. | 5 | $88 |
| Alkermes, Inc. | 3 | $83 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
Products named: CAPLYTA, BRIXADI, BREZTRI, QULIPTA, VRAYLAR, TRELEGY ELLIPTA, JARDIANCE, REXULTI.
Industry payments across PA — which companies pay providers there.
